March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
EGRIFTA WR™ has received FDA approval for use in adults with HIV and lipodystrophy to reduce excess abdominal fat with once-weekly reconstitution and a lower injection volume.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.
FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.